Conmed Corp Stock Price, News & Analysis

CONMED Corporation (NYSE: CNMD) has appointed Kim Kelderman to its Board of Directors, effective September 8, 2025. Kelderman currently serves as President, CEO, and Board member of Bio-Techne (NASDAQ: TECH) since February 2024.

Kelderman brings extensive experience in life sciences, having previously held leadership positions at Thermo Fisher Scientific, where he led multiple businesses and managed the Platforms and Content of the Genetic Sciences Division. Prior to that, he served as Senior Segment Leader at Becton Dickinson, overseeing the global Blood Tubes "Vacutainer" business.

CONMED Corporation (NYSE: CNMD) has announced a quarterly cash dividend of $0.20 per share. The dividend was declared by the Board of Directors on August 7, 2025. Shareholders of record as of September 15, 2025 will receive the dividend payment on October 3, 2025.

CONMED Corporation (NYSE: CNMD) reported Q2 2025 financial results with sales of $342.3 million, representing a 3.1% year-over-year increase. The company's domestic revenue grew 2.8%, while international revenue rose 3.4%. GAAP diluted EPS decreased to $0.69 from $0.96 in Q2 2024, while adjusted diluted EPS improved to $1.15 from $0.98.

The company updated its 2025 guidance, now expecting full-year revenue between $1.356-1.378 billion and adjusted diluted EPS of $4.40-$4.55. This guidance includes an estimated $0.09 EPS negative impact from recent tariff announcements in H2 2025.

Single-use products showed strong performance with 6.6% growth, while capital products declined 15.5%. The company's focus remains on strengthening supply chain operations and executing on four key growth drivers.

CONMED Corporation (NYSE: CNMD) announced that Martha Aronson will step down from its Board of Directors, effective July 7, 2025, to become President and CEO of Merit Medical. Aronson, who joined CONMED's Board in February 2016 and served as Board Chair, has been recognized for her strategic insights and contributions to the company's growth and governance.

The announcement includes statements from Pat Beyer, CONMED's President and CEO, and LaVerne Council, current Chair of the Board, both acknowledging Aronson's valuable service and leadership during her tenure since 2016.

CONMED Corporation (NYSE: CNMD) has scheduled its second quarter 2025 financial results announcement for July 30, 2025, after market close. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results.

Investors can participate in the conference call via telephone by pre-registering to obtain dial-in details. Additionally, a webcast will be available through the "Investors" section of CONMED's website, with a replay accessible approximately one hour after the call concludes.

CONMED Corporation (NYSE: CNMD) has announced the appointment of LaVerne Council as the new Independent Chair of its Board of Directors, effective May 21, 2025. Council will succeed Martha Goldberg Aronson, who will continue to serve as a Director. The change reflects CONMED's commitment to periodic Board and Committee Chair rotations.

Council, recognized for her global operations and information technology expertise, expressed commitment to working with the Board and leadership team to execute the company's long-term strategy. The company aims to empower healthcare providers, deliver stockholder returns, create an engaging employee environment, and drive business success.

CONMED Corporation (NYSE: CNMD) has announced a quarterly cash dividend payment. The company's Board of Directors has declared a dividend of $0.20 per share. The dividend was declared on May 20, 2025, and will be paid on July 3, 2025 to shareholders who are on record as of June 13, 2025.

CONMED Corporation reported Q1 2025 financial results with sales of $321.3 million, showing a 2.9% year-over-year increase. The company saw domestic revenue growth of 4.2% and international revenue growth of 1.2% (3.4% in constant currency).

Key financial metrics include:

• GAAP diluted earnings per share dropped to $0.19 from $0.63 in Q1 2024
• Adjusted diluted earnings rose to $0.95 from $0.79 year-over-year
• Gross profit margin improved to 55.3% from 55.1%

The company updated its 2025 outlook, now expecting full-year revenue between $1.350-1.378 billion and adjusted EPS of $4.45-4.60. However, recent tariff announcements could impact EPS by approximately $0.14 in H2 2025. The company noted reduced currency headwinds of 50-70 basis points, down from previous estimates of 100-120 basis points.

CONMED (NYSE: CNMD) has scheduled its first quarter 2025 financial results announcement for April 30, 2025, after market close. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the quarterly performance. Interested participants can pre-register to obtain dial-in details and passcode. The call will also be available via webcast through CONMED's investor relations website, with a replay accessible approximately one hour after the call conclusion.